Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic‐intermittent L‐dopa and A2A receptor blockade plus L‐Dopa in dopamine‐denervated rats
- 12 March 2002
- Vol. 44 (3) , 166-174
- https://doi.org/10.1002/syn.10066
Abstract
Adenosine A2A receptor antagonists have been proposed as an effective therapy in the treatment of Parkinson's disease. In the present study, we compared the modifications on striatal glutamate decarboxylase (GAD67), enkephalin, and dynorphin mRNA levels produced by a chronic‐intermittent administration of L‐3,4‐dihydroxyphenyl‐alanine (L‐dopa) (6 mg/kg) with those produced by the adenosine A2A receptor antagonist SCH 58261 (5 mg/kg) plus L‐dopa (3 mg/kg) in unilaterally 6‐hydroxydopamine (6‐OHDA)‐lesioned rats. As previously reported, L‐dopa (6 mg/kg) and SCH 58261 (5 mg/kg) plus L‐dopa (3 mg/kg) produced the same degree of turning behavior after the first administration. However, while L‐dopa (6 mg/kg) induced a sensitized turning behavior response during the course of the treatment, which indicated a dyskinetic potential, SCH 58261 (5 mg/kg) plus L‐dopa (3 mg/kg) produced a stable turning behavior response, which was predictive of absence of dyskinetic side effects. Unilateral 6‐OHDA lesion produced an elevation in striatal GAD67 and enkephalin mRNA levels and to a decrease in dynorphin mRNA levels. Chronic‐intermittent L‐dopa (6 mg/kg) treatment increased the striatal levels of GAD67, dynorphin, and enkephalin mRNA in the lesioned side as compared to the vehicle treatment. Chronic‐intermittent SCH 58261 (5 mg/kg) plus L‐dopa (3 mg/kg) as well as L‐dopa (3 mg/kg) or SCH 58261 (5 mg/kg) alone did not produce any significant modification in GAD67, dynorphin, or enkephalin mRNA levels in the lesioned striatum as compared to the striatum of vehicle‐treated rats. The results show that combined SCH 58261 plus L‐dopa did not produce long‐term changes in markers of striatal efferent neurons activity and suggest that the lack of modifications in GAD67 and dynorphin mRNA after SCH 58261 plus L‐dopa might correlate with the lack of turning behavior sensitization which predicts drug dyskinetic potential. Synapse 44:166–174, 2002.Keywords
This publication has 54 references indexed in Scilit:
- Turning off cortical ensembles stops striatal Up states and elicits phase perturbations in cortical and striatal slow oscillations in rat in vivoThe Journal of Physiology, 2006
- L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNAEuropean Journal of Neuroscience, 1998
- Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's diseaseTrends in Pharmacological Sciences, 1997
- Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's diseaseTrends in Pharmacological Sciences, 1997
- Enhancement of the Behavioral Response to Apomorphine Administration Following Repeated Treatment in the 6-Hydroxydopamine-Lesioned Rat Is Temporally Correlated with a Rise in Striatal Preproenkephalin-B, but Not Preproenkephalin-A, Gene ExpressionExperimental Neurology, 1997
- Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned ratsBrain Research, 1996
- Effects of Nigrostriatal Denervation and L‐Dopa Therapy on the GABAergic Neurons of the Striatum in MPTP‐treated Monkeys and Parkinson's Disease: An In Situ Hybridization Study of GAD67 mRNAEuropean Journal of Neuroscience, 1995
- D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal NeuronsScience, 1990
- Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesionsBrain Research, 1987